Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event
- PMID: 31461381
- DOI: 10.1200/JCO.19.01623
Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event
Abstract
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.
Similar articles
-
Late Breast Cancer Survivorship: Side Effects and Care Recommendations.J Clin Oncol. 2022 May 20;40(15):1604-1610. doi: 10.1200/JCO.22.00049. Epub 2022 Feb 28. J Clin Oncol. 2022. PMID: 35226513 Free PMC article. Review.
-
Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung Cancer.J Clin Oncol. 2022 Sep 1;40(25):2871-2877. doi: 10.1200/JCO.22.00873. Epub 2022 Jun 17. J Clin Oncol. 2022. PMID: 35714306 Review.
-
How We Approach Smoldering Multiple Myeloma.J Clin Oncol. 2020 Apr 10;38(11):1119-1125. doi: 10.1200/JCO.19.02834. Epub 2020 Jan 31. J Clin Oncol. 2020. PMID: 32004107 Free PMC article.
-
Tailored Approaches to Induction Therapy for Acute Promyelocytic Leukemia.J Clin Oncol. 2017 Feb 20;35(6):583-586. doi: 10.1200/JCO.2016.68.4761. Epub 2017 Jan 17. J Clin Oncol. 2017. PMID: 28095152 Review.
-
Late Recurrence Following Early Breast Cancer.J Clin Oncol. 2022 May 1;40(13):1400-1406. doi: 10.1200/JCO.22.00167. Epub 2022 Mar 3. J Clin Oncol. 2022. PMID: 35239445 Free PMC article. Review.
Cited by
-
Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies.Yonsei Med J. 2023 Oct;64(10):587-592. doi: 10.3349/ymj.2023.0063. Yonsei Med J. 2023. PMID: 37727917 Free PMC article.
-
Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma.J Liver Cancer. 2022 Sep;22(2):93-102. doi: 10.17998/jlc.2022.03.28. Epub 2022 Apr 22. J Liver Cancer. 2022. PMID: 37383404 Free PMC article. Review.
-
Current Status in Rechallenge of Immunotherapy.Int J Biol Sci. 2023 May 7;19(8):2428-2442. doi: 10.7150/ijbs.82776. eCollection 2023. Int J Biol Sci. 2023. PMID: 37215995 Free PMC article. Review.
-
Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report.World J Clin Cases. 2022 Aug 16;10(23):8284-8290. doi: 10.12998/wjcc.v10.i23.8284. World J Clin Cases. 2022. PMID: 36159517 Free PMC article.
-
Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis.Front Oncol. 2022 Jun 23;12:877434. doi: 10.3389/fonc.2022.877434. eCollection 2022. Front Oncol. 2022. PMID: 35814436 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
